Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO Virtual Plenary on-demand resources


Monthly presentations of the latest, original scientific data from randomized phase III trials in oncology, or from phase II trials which demonstrate remarkable therapeutic benefit, scientific insight or progress in an area of unmet need.

Virtual Plenary: 27-28 March 2023

Immunotherapy+chemotherapy for the treatment of primary advanced or recurrent endometrial cancer: The placebo-controlled randomised phase III RUBY trial

Presenter: Mansoor Mirza, Denmark; Discussant: Ilaria Colombo, Switzerland; AACR expert commentary: Elise C. Kohn, USA

Virtual Plenary: 16-17 February 2023

Immunotherapy plus chemotherapy as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction cancer: Phase III KEYNOTE-859 study

Presenter: Sun Young Rha, Republic of Korea; Discussant: Elizabeth Smyth, UK; AACR expert commentary: Brian S. Henick, USA

Virtual Plenary: 15-16 December 2022

The NORA Trial: PARP inhibitor with individualized starting dose as maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer, ad hoc interim overall survival results

Presenter: Mansoor Mirza, Denmark; Discussant: Antonio González-Martín, Spain

Virtual Plenary: 14-15 July 2022

Adjuvant immunotherapy combination in patients with early HER-2 positive breast cancer in APHINITY: 8.4 years' follow-up

Presenter: Sibylle Loibl, Germany; Discussant: Javier Cortés, Spain;

Virtual Plenary: 19-20 May 2022

Updated progression-free survival (PFS) and depth of response in IKEMA, a randomized phase III trial of immunotherapy combination (Isa-Kd) vs Kd in relapsed multiple myeloma (MM)

Presenter: Philippe Moreau, France; Discussant: Francesca Gay, Italy;

Virtual Plenary: 17-18 March 2022

Immunotherapy versus placebo for early-stage non-small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy (chemo) when indicated: Randomized, triple-blind, phase III EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 study

Presenter: Luis Paz-Ares, Spain; Discussant: Martin Reck, Germany;

Virtual Plenary: 17-18 March 2022

Prospective double-blind, randomized phase III ENGOT-EN5/GOG-3055/SIENDO study of oral selective inhibitors of nuclear export/placebo as maintenance therapy after first-line chemotherapy for advanced or recurrent endometrial cancer

Presenter: Ignace Vergote, Belgium; Discussant: Amit Oza, Canada;

Virtual Plenary: 16-17 March 2022

Pre-specified event driven analysis of Overall Survival (OS) in the OlympiA phase III trial of adjuvant PARP inhibitor in germline BRCA1/2 mutation (gBRCAm) associated breast cancer

Presenter: Andrew Tutt, UK; Discussant: Mark Robson, USA;

Virtual Plenary: 16-17 December 2021

Combined chemotherapy plus immunotherapy as first line treatment for patients with metastatic colorectal cancer (mCRC) ineligible for intensive therapy: The phase III randomized SOLSTICE study

Presenter: Thierry André, France; Discussant: Demetris Papamichael, Cyprus;

Virtual Plenary: 20 November, from ESMO ASIA VIRTUAL ONCOLOGY WEEK 2021

TKI plus immunotherapy as first-line systemic treatment for advanced hepatocellular carcinoma (aHCC): Results from the randomized phase III COSMIC-312 trial

Presenter: Robin Kate Kelley, San Francisco, USA; Discussant: Ian Chau, Sutton, UK;

Virtual Plenary: 19 November, from ESMO ASIA VIRTUAL ONCOLOGY WEEK 2021

ORIENT-31: Phase III study of immune checkpoint inhibitor with or without anti-angiogenic therapy plus chemotherapy in patients with EGFR mutated nonsquamous NSCLC who progressed after EGFR-TKI therapy

Presenter: Shun Lu, Shanghai, China; Discussant: Myung-Ju Ahn, Seoul, Republic of Korea (South Korea);

Virtual Plenary: 14-15 October 2021

Adjuvant kinase inhibitor Combined with Endocrine Therapy (ET) in Early Breast Cancer: Updated Results from MonarchE

Presenter: Joyce O'Shaughnessy, USA; Discussant: Aditya Bardia, USA;

Virtual Plenary: 15-16 July 2021

KEYNOTE-522: Phase III study of neoadjuvant immunotherapy + chemotherapy vs. placebo + chemotherapy, followed by adjuvant immunotherapy vs. placebo for early-stage TNBC

Presenter: Peter Schmid, UK; Discussant: Giuseppe Curigliano, Italy;

Virtual Plenary: 17-18 June 2021

IMpassion050: A phase 3 study of neoadjuvant immunotherapy triplet + chemotherapy in high-risk, HER2-positive early breast cancer

Presenter: Jens Huober, Switzerland; Discussant: Evandro de Azambuja, Belgium;

Virtual Plenary: 17-18 June 2021

IMpower133: Gene expression analysis in long-term survivors with ES-SCLC treated with first-line chemotherapy + immunotherapy

Presenter: Stephen Liu, USA; Discussant: Anne-Marie Dingemans, the Netherlands;

Virtual Plenary: 12-13 May 2021

Randomised Phase III Trial Data on the Efficacy and Safety of immunotherapy as Opposed to Chemotherapy in Patients with Progressive Advanced Cervical Cancer

Presenter: Krishnansu S. Tewari, USA; Discussant: Mansoor Mirza, Denmark;

Virtual Plenary: 12-13 May 2021

Randomised Phase II Trial Data on the Combination of 2nd-line Kinase Inhibitor (KI) and Immunotherapy Versus Standard of Care KI in EGFR T790M-mutated Advanced NSCLC

Presenter: Ross Soo, Singapore; Discussant: Edward Garon, USA;

Virtual Plenary: 8-9 Apr 2021

Effectiveness of immunotherapy alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small cell lung cancer (Nsq-NSCLC) with high PD-L1 expression using real-world data

Presenter: Solange Peters, Switzerland; Discussant: Federico Cappuzzo, Italy;

Virtual Plenary: 19 Feb 2021

Efficacy of Kinase Inhibitor in Patients With HR+/HER2- High Risk Early Stage Breast Cancer

Presenter: Thomas Bachelot, France; Discussant: Peter Schmid, UK;

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.